Skip Navigation


Robert P. Byington, Ph.D.Wake Forest School of Medicine

Robert P. Byington, Ph.D.


Contact Information

Academic: 336-716-2885 | Department: 336-716-2011


Education & Training

  • B.S., Loyola College in Maryland, 1974
  • M.P.H., University of Texas School of Public Health-Hous, 1976
  • Ph.D., University of Texas School of Public Health-Hous, 1984
  • Fellowship, Northwestern University Medica, 1977
Robert P. Byington, Ph.D.

Robert P. Byington, Ph.D.

Professor, Epidemiology & Prevention

Research Interests

Hydroxymethylglutaryl-CoA Reductase Inhibitors; Diabetes Mellitus, Type 2; Cardiovascular Diseases; Hypoglycemic Agents; Simvastatin
More »

Contact Information

Academic: 336-716-2885 | Department: 336-716-2011


Recent Publications

Association between mean systolic blood pressure and cardiovascular outcomes in diabetes mellitus: ACCORD trial. Yeboah J, Byington B, Bertoni A.. J Hum Hypertens. 2018;32(2):167-169.

Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, Lopez C, O'Connor PJ, Sweeney ME, Weiss D, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm R, Ismail-Beigi F, Goff DC Jr, Fleg JL, Rosenberg Y, Byington RP.. JAMA Cardiol. 2017;2(4):370-380.

Social participation modifies the effect of a structured physical activity program on major mobility disability among older adults: results from the LIFE study. Corbett DB, Rejeski WJ, Tudor-Locke C, Glynn NW, Kritchevsky SB, McDermott MM, Church TS, Fielding RA, Gill TM, King AC, Miller ME, Chen H, Pahor M, Manini TM, Pahor M, Guralnik JM, Leeuwenburgh C, Caudle C, Crump L, Holmes L, Lee J,.. J Gerontol B Psychol Sci Soc Sci. 2017;():.

The feasibility of walnut and extra virgin olive oil supplementation in older adults. Vitolins MZ, Blackwell CS, Williamson JD, Foy CG, Wilmoth S, Sink KM, Reynolds LM, Byington RP, Reboussin DM.. Int J Food Nutr Sci. 2017;4(1):1-6.

Fibroblast growth factor 23 and incident CKD in type 2 diabetes. Isakova T, Craven TE, Lee J, Scialla JJ, Xie H, Wahl P, Marcovina SM, Byington RP, Wolf M.. Clin J Am Soc Nephrol. 2015;10(1):29-38.

Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure trial. Soliman EZ, Byington RP, Bigger JT, Evans G, Okin PM, Goff DC Jr, Chen H.. Hypertension. 2015;66(6):1123-1129.

Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD trial. Miller ME, Williamson JD, Gerstein HC, Byington RP, Cushman WC, Ginsberg HN, Ambrosius WT, Lovato L, Applegate WB.. Diabetes Care. 2014;37(3):634-643.

Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Linz PE, Lovato LC, Byington RP, O'Connor PJ, Leiter LA, Weiss D, Force RW, Crouse JR, Ismail-Beigi F, Simmons DL, Papademetriou V, Ginsberg HN, Elam MB.. Diabetes Care. 2014;37(3):686-693.

Long-term effects of intensive glucose lowering on cardiovascular outcomes. Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Byington RP, et al.. N Engl J Med. 2011;364(9):818-828.

Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Goff DC Jr, Malozowski S, Margolis KL, Probstfield JL, et al.. Diabetes Care. 2010;33(5):983-990.

Effects of intensive blood-pressure control in type 2 diabetes mellitus. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, et al.. N Engl J Med. 2010;362(17):1575-1585.

Effects of combination lipid therapy in type 2 diabetes mellitus. Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, Linz P, Friedewald WT, Buse JB, Goff DC Jr, Byington RP, et al.. N Engl J Med. 2010;362(17):1563-1574.

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, et al.. BMJ. 2010;340():b4909.

Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials. Mount DL, Feeney P, Fabricatore AN, Coday M, Bahnson J, Byington R, Phelan S, Wilmoth S, Knowler WC, Espeland MA, et al.. Clin Trials. 2009;6(5):416-429.

Intensive glucose control and macrovascular outcomes in type 2 diabetes. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, et al.. Diabetologia. 2009;52(11):2288-2298.

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Furberg C, Byington R, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C, et al.. Lancet. 2008;371(9607):117-125.

Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. Agodoa L, Anderson C, Chalmers J, MacMahon S, Neal B, Asselbergs FW, van Gilst WH, Baigent C, Byington R, Turnbull F, et al.. BMJ. 2008;336(7653):1121-1123.

Effects of intensive glucose lowering in type 2 diabetes. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, et al.. N Engl J Med. 2008;358(24):2545-2559.

Intensive glucose control in type 2 diabetes [reply to letter]. Byington RP, Gerstein HC, Friedewald WT.. N Engl J Med. 2008;359(14):1520-1521.

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: design and methods. Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, et al.. Am J Cardiol. 2007;99(12 Suppl 1):S21-S33.

Introduction. Byington RP, Genuth S, Friedewald WT, Simons-Morton DG.. Am J Cardiol. 2007;99(12 Suppl 1):1-3.

Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Goff DC Jr, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, Buse JB, Genuth S, Probstfield JL, Simons-Morton DG.. Am J Cardiol. 2007;99(12 Suppl 1):S4-S20.

Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. Agodoa L, Anderson C, Asseibergs F, Baigent C, Black H, Brenner B, Brown M, Bulpitt C, Byington R, Turnbull F, et al.. J Hypertens. 2007;25(7):951-958.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Robert P. Byington, Ph.D.

Robert P. Byington, Ph.D.

Professor, Epidemiology & Prevention

Quick Reference

Request an Appointment
New Patients


Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Wake Forest Baptist Ranked among Nation’s ‘Best Hospitals’  25 Years in a Row by U.S. News & World ReportComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsNursing Magnet StatusJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.